![\"chart](\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2017\/06\/chart-1.png\")
<\/a><\/p>\nNEW FILINGS<\/strong><\/span><\/p>\n Company: Vencore Holding Corp.<\/strong> Company: Kala Pharmaceuticals, Inc.<\/strong> Company: Calyxt, Inc.<\/strong> Company: YogaWorks, Inc. Company: PetIQ, Inc.<\/strong> TERMS ADDED<\/strong><\/span><\/p>\n Company: Esquire Financial Holdings<\/strong> Company: Dova Pharmaceuticals, Inc.<\/strong> Company: Byline Bancorp, Inc.<\/strong> Company: Blue Apron Holdings, Inc.<\/strong> Company: Aileron Therapeutics, Inc.<\/strong> Company: Akcea Therapeutics, Inc.<\/strong> New Filings & Updated Terms (Week ending 6.23.17) IPO Boutique keeps apprised of the active pipeline. Currently there are 56 active IPOs in the pipeline as of June 2, 2016. No SPACs or Unit Offerings are included. NEW FILINGS Company: Vencore Holding Corp. Symbol: VNCR Description: Vencore is a leading provider of mission-critical, innovation-driven services[…]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24],"tags":[1140,1239,1235,1232,1266,1233,1268,1267],"class_list":["post-2420","post","type-post","status-publish","format-standard","hentry","category-ipo","tag-akca","tag-alrn","tag-aprn","tag-by","tag-dova","tag-esq","tag-kala","tag-vncr"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=2420"}],"version-history":[{"count":7,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2420\/revisions"}],"predecessor-version":[{"id":2509,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/2420\/revisions\/2509"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=2420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=2420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=2420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nSymbol: VNCR
\nDescription: Vencore is a leading provider of mission-critical, innovation-driven services and solutions to U.S. Government customers.
\nTrade Date: TBD
\nUnderwriter(s): Goldman Sachs & Co., Wells Fargo Securities
\nTerms Added: 6-21-17
\nListed Cash Raise: $250 million<\/p>\n
\nSymbol: KALA
\nDescription: They are a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.
\nTrade Date: TBD
\nUnderwriter(s): J.P. Morgan, BofA Merrill Lynch, Wells Fargo Securities
\nCo-Manager: Wedbush PacGrow
\nFiled: 6-23-17
\nListed Cash Raise: $86.25 million<\/p>\n
\nSymbol: TBD
\nDescription: They are a consumer-centric, food- and agriculture-focused company. By combining our leading gene-editing technology and technical expertise with our innovative commercial strategy, we are pioneering a paradigm shift to deliver healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, to farmers.
\nTrade Date: TBD
\nUnderwriter(s): Citigroup, Credit Suisse, Jefferies, Wells Fargo Securities
\nCo-Manager: Ladenburg Thalmann
\nFiled: 6-23-17
\nListed Cash Raise: $50 million<\/p>\n
\nSymbol: YOGA
\nDescription: They are one of the largest and fastest growing providers of high quality yoga instruction in the U.S., with almost 3 million student visits in 2016 and 50 company-owned studios as well as our Internet-based digital media service, MyYogaWorks.com
\nTrade Date: TBD
\nUnderwriter(s): Cowen and Company, Stephens Inc., Guggenheim Securities
\nFiled: 6-23-17
\nListed Cash Raise: $74.75 million<\/p>\n
\nSymbol: PETQ
\nDescription: PetIQ is a rapidly growing distributor and manufacturer of veterinarian-grade pet prescription medications, over-the-counter flea and tick preventatives and health and wellness products for dogs and cats.
\nTrade Date: TBD
\nUnderwriter(s): Jefferies, William Blair
\nCo-Manager(s): Oppenheimer & Co., Raymond James, SunTrust Robinson Humphrey
\nFiled: 6-23-17
\nListed Cash Raise: $85 million<\/p>\n
\nSymbol: ESQ
\nDescription: They are a bank holding company headquartered in Jericho, New York and registered under the Bank Holding Company Act of 1956, as amended (the BHC Act).
\nTrade Date: 6\/27
\nPrice: $14.00-$16.00
\nShares 2.56 million
\nUnderwriter(s): Sandler O’ Neill + Partners
\nTerms Added: 6-19-17<\/p>\n
\nSymbol: DOVA
\nDescription: They are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count.
\nTrade Date: 6\/28
\nPrice Range: $15.00-$17.00
\nShares: 4.06 million
\nUnderwriter(s): J.P. Morgan, Jefferies, Leerink Partners
\nTerms Added: 6-19-17<\/p>\n
\nSymbol: BY
\nDescription: They are a bank holding company headquartered in Chicago, Illinois and conduct all our business activities through our subsidiary, Byline Bank, a full service commercial bank.
\nTrade Date: 6\/29
\nPrice Range: $19.00-$21.00
\nShares: 5.7 million
\nUnderwriter(s): BofA Merrill Lynch, Keefe Bruyette & Woods
\nCo-Manager(s): Piper Jaffray, Sandler O\u2019Neill + Partners, Stephens Inc.
\nTerms Added: 6-19-17<\/p>\n
\nSymbol: APRN
\nDescription: Blue Apron was founded in 2012 premised on a simple desire\u2014our founders wanted to cook at home with their families, but they found grocery shopping and menu planning burdensome, time consuming, and expensive.
\nTrade Date: 6\/29
\nPrice Range: $15.00-$17.00
\nShares: 30 million
\nUnderwriter(s): Goldman Sachs & Co., Morgan Stanley, Citigroup, Barclays
\nCo-Manager(s): RBC Capital Markets, SunTrust Robinson Humphrey, Stifel, Canaccord Genuity, Needham & Company, Oppenheimer & Co., Raymond James, William Blair
\nTerms Added: 6-19-17<\/p>\n
\nSymbol: ALRN
\nDescription: They are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides.
\nTrade Date: 6\/29
\nPrice Range: $15.00-$17.00
\nShares: 3.75 million
\nUnderwriter(s): BofA Merrill Lynch, Jefferies
\nCo-Manager(s): William Blair, Canaccord Genuity
\nTerms Added: 6-19-17<\/p>\n
\nSymbol: AKCA
\nDescription: They are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders.
\nTrade Date: 6\/30
\nPrice Range: $12.00-$14.00
\nShares: 9.62 million
\nUnderwriter(s): Cowen and Company, Stifel, Wells Fargo Securities
\nCo-Manager(s): BMO Capital Markets
\nTerms Added: 6-20-17<\/p>\n","protected":false},"excerpt":{"rendered":"